Experimental drug shows promise for kaposi sarcoma lesions
NCT ID NCT07539454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called nirogacestat in 28 people with Kaposi sarcoma skin tumors. The drug blocks a protein that helps tumors grow, aiming to shrink lesions and stop them from spreading. While not a cure, it may offer a new way to control the disease in people who haven't responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States